Primary End Point: Major Adverse Cardiovascular Event

Risk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers represent risk ratios and horizontal lines the 95% confidence intervals with marker size reflecting the statistical weight of the study using inverse variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% confidence intervals for major adverse cardiovascular events. There was no significant between-trial heterogeneity (Q statistic = 8.36, d.f.  = 5; P = 0.14; I² = 40%).

CV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction.

Reprinted from Udell JA et al, Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials, Eur Heart J, 2015, by permission of Oxford University Press.